MX2020003616A - Nuevo derivado de fenilpiridina y composicion farmaceutica que lo contiene. - Google Patents

Nuevo derivado de fenilpiridina y composicion farmaceutica que lo contiene.

Info

Publication number
MX2020003616A
MX2020003616A MX2020003616A MX2020003616A MX2020003616A MX 2020003616 A MX2020003616 A MX 2020003616A MX 2020003616 A MX2020003616 A MX 2020003616A MX 2020003616 A MX2020003616 A MX 2020003616A MX 2020003616 A MX2020003616 A MX 2020003616A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
composition containing
containing same
phenylpyridine derivative
novel phenylpyridine
Prior art date
Application number
MX2020003616A
Other languages
English (en)
Inventor
Wol-Young Kim
Jung-Eun Park
Keuk-Chan Bang
Joon-Seok Park
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of MX2020003616A publication Critical patent/MX2020003616A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente divulgación se refiere a un nuevo derivado de fenilpiridina representado por la Fórmula química 1 y a una composición farmacéutica que comprende el mismo, y el compuesto según la presente divulgación puede usarse de manera útil para la prevención o el tratamiento de enfermedades autoinmunitarias o cánceres.
MX2020003616A 2017-10-11 2018-10-11 Nuevo derivado de fenilpiridina y composicion farmaceutica que lo contiene. MX2020003616A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170131349A KR102613433B1 (ko) 2017-10-11 2017-10-11 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
PCT/KR2018/011913 WO2019074275A1 (ko) 2017-10-11 2018-10-11 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
MX2020003616A true MX2020003616A (es) 2020-07-28

Family

ID=66101569

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003616A MX2020003616A (es) 2017-10-11 2018-10-11 Nuevo derivado de fenilpiridina y composicion farmaceutica que lo contiene.

Country Status (23)

Country Link
US (1) US11149019B2 (es)
EP (1) EP3696176B1 (es)
JP (1) JP6876873B2 (es)
KR (2) KR102613433B1 (es)
CN (1) CN111212833B (es)
AU (1) AU2018349293B2 (es)
BR (1) BR112020007177A2 (es)
CA (1) CA3076667C (es)
CL (1) CL2020000940A1 (es)
CO (1) CO2020004319A2 (es)
DO (1) DOP2020000077A (es)
EC (1) ECSP20021379A (es)
ES (1) ES2915583T3 (es)
MA (1) MA50368A (es)
MX (1) MX2020003616A (es)
MY (1) MY194695A (es)
NZ (1) NZ763263A (es)
PH (1) PH12020550252A1 (es)
RU (1) RU2748945C1 (es)
SA (1) SA520411726B1 (es)
SG (1) SG11202002422WA (es)
TN (1) TN2020000050A1 (es)
WO (1) WO2019074275A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200070297A (ko) 2017-10-11 2020-06-17 에프. 호프만-라 로슈 아게 Rip1 키나아제 억제제로서 사용하기 위한 이환형 화합물
CN115151537B (zh) * 2020-02-26 2024-09-06 株式会社大熊制药 制备杂环胺衍生物的方法
KR102531088B1 (ko) * 2020-02-26 2023-05-10 주식회사 대웅제약 헤테로사이클릭아민 유도체의 제조 방법
WO2024182552A1 (en) * 2023-03-01 2024-09-06 Uereka Biosciences, Inc. Lzk inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1347971T3 (da) 2000-12-21 2006-05-15 Bristol Myers Squibb Co Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
EP1697508A2 (en) 2003-12-05 2006-09-06 Vertex Pharmaceuticals, Inc. Crystal structure of interleukin-2 tyrosine kinase (itk) and binding pockets thereof
US20070032403A1 (en) 2003-12-30 2007-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Crystal structure of the ITK kinase domain
US7429605B2 (en) 2005-08-04 2008-09-30 Hoffmann-La Roche Inc. Phenylpyridine derivatives
TW200811134A (en) * 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
AR063706A1 (es) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
PL2529621T3 (pl) 2006-09-22 2017-06-30 Pharmacyclics Llc Inhibitory kinazy tyrozynowej brutona
JP2010529193A (ja) 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
ES2444777T3 (es) 2009-06-12 2014-02-26 Bristol-Myers Squibb Company Compuestos de nicotinamida útiles como moduladores de quinasas
RU2598852C2 (ru) * 2010-06-23 2016-09-27 Ханми Сайенс Ко., Лтд. Новые конденсированные пиримидиновые производные для ингибирования тирозинкиназной активности
EP2588471A1 (en) * 2010-06-30 2013-05-08 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
WO2012035055A1 (en) * 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP2890691B1 (en) 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
CN104822663B (zh) * 2012-10-04 2017-03-08 犹他大学研究基金会 作为酪氨酸受体激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
DK3035936T3 (da) * 2013-08-23 2019-06-11 Neupharma Inc Visse kemiske enheder, sammensætninger og fremgangsmåder
KR20160063366A (ko) * 2013-10-21 2016-06-03 메르크 파텐트 게엠베하 Btk 저해제로서 헤테로아릴 화합물 및 이들의 용도
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015157556A1 (en) 2014-04-09 2015-10-15 Kadmon Corporation, Llc Treatment of gvhd
US9717745B2 (en) * 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases

Also Published As

Publication number Publication date
RU2748945C1 (ru) 2021-06-02
PH12020550252A1 (en) 2021-02-22
TN2020000050A1 (en) 2021-10-04
SG11202002422WA (en) 2020-04-29
CN111212833A (zh) 2020-05-29
US11149019B2 (en) 2021-10-19
AU2018349293A1 (en) 2020-04-23
AU2018349293B2 (en) 2020-10-08
ES2915583T3 (es) 2022-06-23
EP3696176A4 (en) 2021-03-17
MY194695A (en) 2022-12-15
SA520411726B1 (ar) 2022-06-27
JP2020536093A (ja) 2020-12-10
EP3696176B1 (en) 2022-05-04
JP6876873B2 (ja) 2021-05-26
WO2019074275A1 (ko) 2019-04-18
CA3076667C (en) 2022-06-21
KR102613433B1 (ko) 2023-12-13
KR20220066012A (ko) 2022-05-23
CL2020000940A1 (es) 2020-09-04
BR112020007177A2 (pt) 2020-09-24
CN111212833B (zh) 2022-09-06
ECSP20021379A (es) 2020-05-29
KR20190040773A (ko) 2019-04-19
MA50368A (fr) 2021-03-17
EP3696176A1 (en) 2020-08-19
NZ763263A (en) 2023-02-24
US20200223821A1 (en) 2020-07-16
CO2020004319A2 (es) 2020-04-24
DOP2020000077A (es) 2020-08-15
CA3076667A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
MX2020003596A (es) Composiciones de acido nucleico-polipeptido y usos de las mismos.
GEP20217239B (en) Pharmaceutical composition
MX2020004084A (es) Agentes farmaceuticos como inhibidores del rsv para utilizar en combinacion.
SG10201803042PA (en) Anti-tim-3 antibodies
MY191581A (en) Anti-pd-1 antibodies
MX2019007021A (es) Anticuerpos il-11ra.
CA2956871C (en) Compounds active towards bromodomains
EP3569671A4 (en) METHYLMENTHOLDER DERIVATIVE AND COMPOSITION THEREOF TO EXERCISE A COOLING EFFECT
PH12016502142B1 (en) Anti-ptk7 antibody-drug conjugates
SG10201902326XA (en) Mk2 inhibitors and uses thereof
MX2020003760A (es) Formulaciones de niraparib.
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2020004071A (es) Derivados de aztreonam y usos de los mismos.
MX2020003616A (es) Nuevo derivado de fenilpiridina y composicion farmaceutica que lo contiene.
MX2020004424A (es) Formulacion aerosolizable.
GEP20217240B (en) Pharmaceutical composition
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
EP3318282A4 (en) DRUG DELIVERY VECTOR, AND COMPOSITION CONTAINING THE SAME
MX2020004455A (es) Derivados de pirrolopirazina como inhibidores de integrina alfa v.
PH12017502028A1 (en) Vortioxetine pyroglutamate
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
MX2020004422A (es) Formulacion vaporizable saborizada.